Ketcher 12212315572D 1 1.00000 0.00000 0 28 31 0 1 0 999 V2000 14.4860 -4.7711 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 11.8028 -6.0800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 12.6690 -6.5799 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 11.8028 -5.0800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 12.6690 -4.5800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 13.5349 -6.0800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 13.5349 -5.0800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 13.5349 -4.0800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 15.0737 -5.5800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 14.4860 -6.3890 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 10.9369 -6.5800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 10.9370 -7.5801 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 12.6690 -7.5799 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 11.8031 -8.0799 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 10.0708 -6.0801 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 9.2049 -6.5803 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 10.0711 -8.0802 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 9.2050 -7.5803 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 10.9368 -5.5800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 8.3390 -8.0805 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 12.6690 -5.5799 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0 13.5349 -7.0800 0.0000 H 0 0 0 0 0 0 0 0 0 0 0 0 16.0737 -5.5800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 14.2781 -3.7929 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 15.2291 -4.1019 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 15.0213 -3.1238 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 13.3270 -3.4839 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 14.8133 -2.1456 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 2 4 2 0 0 0 4 5 1 0 0 0 3 6 1 0 0 0 5 7 1 0 0 0 7 8 1 1 0 0 7 1 1 0 0 0 7 6 1 0 0 0 1 9 1 0 0 0 6 10 1 0 0 0 9 10 1 0 0 0 2 11 1 0 0 0 2 3 1 0 0 0 3 13 1 0 0 0 12 14 1 0 0 0 13 14 1 0 0 0 11 15 1 0 0 0 11 12 1 0 0 0 15 16 2 0 0 0 12 17 2 0 0 0 16 18 1 0 0 0 17 18 1 0 0 0 11 19 1 1 0 0 18 20 2 0 0 0 3 21 1 1 0 0 6 22 1 6 0 0 9 23 1 6 0 0 1 24 1 0 0 0 1 25 1 6 0 0 24 26 1 0 0 0 24 27 2 0 0 0 26 28 1 0 0 0 M END > CHEBI:228304 > vamorolone > A 3-oxo-Δ1,Δ4-steroid that is pregna-1,4,9(11)-trien-17-ol substituted by oxo, oxo, and hydroxy groups at positions 3, 20, and 21, respectively. It is approved by the FDA for the treatment of patients with Duchenne muscular dystrophy aged 2 years and older. > 3 > VBP15; VBP-15; VBP 15; 17alpha,21-dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; (16alpha)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione > 17,21-dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione > vamorolonum; vamorolone; vamorolone; vamorolona > Agamree > C22H28O4 > 356.462 > 356.19876 > 0 > [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)C=C[C@]12C > InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1 > ZYTXTXAMMDTYDQ-DGEXFFLYSA-N > 13209-41-1 > DB15114 > D11000 > Vamorolone > PMC9627259 > 23498916; 23667681; 24014378; 25392236; 27133900; 28030841; 29524454; 29666400; 29883261; 30120816; 30219580; 30742306; 30745312; 31446438; 31451516; 32434278; 32917814; 32956407; 35076703; 36036925; 36816559; 37440999; 37534133; 37819629; 37927274; 38103149; 38153112; 38335499 $$$$